Merck’s Gardasil Halt Shows Blockbuster Shots’ Dilemma in China
Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US pharmaceutical giant made the call earlier this week to halt shipments.
Merck beats estimates on fourth-quarter on earnings
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...
16hon MSN
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
The drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares.
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Palantir stock surges as artificial-intelligence gains drive an earnings and revenue beat, China begins an antitrust probe ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback